Therma Bright Congratulates Investment Partner Inretio's Promising Initial Results from PREVA(TM) Device's First Clinical Phase
Therma Bright (TSXV: THRM) (OTCQB: TBRIF) reports positive initial clinical trial results for the PREVA™ ischemic stroke device developed by its investment partner Inretio. The results were presented at the BRAIN Conference 2024 in London by Dr. Gal Yaniv, Director of Endovascular Neurosurgery from Sheba Medical Center. The first phase of clinical trials showed exceptional outcomes, demonstrating the device's potential to improve stroke care and patient recovery. Inretio's CEO Raviv Vine emphasized the company's mission to save lives through medical innovation. The successful presentation marks a significant milestone as Inretio progresses through its clinical program toward global market entry.
Therma Bright (TSXV: THRM) (OTCQB: TBRIF) ha riportato risultati clinici iniziali positivi per il dispositivo PREVA™ per ictus ischemico sviluppato dal suo partner d'investimento Inretio. I risultati sono stati presentati alla BRAIN Conference 2024 a Londra dal Dott. Gal Yaniv, Direttore della Neurochirurgia Endovascolare del Sheba Medical Center. La prima fase degli studi clinici ha mostrato risultati eccezionali, dimostrando il potenziale del dispositivo nel migliorare le cure per l'ictus e il recupero dei pazienti. Il CEO di Inretio, Raviv Vine, ha sottolineato la missione dell'azienda di salvare vite attraverso l'innovazione medica. La presentazione di successo segna una pietra miliare significativa mentre Inretio progredisce nel suo programma clinico verso l'ingresso nel mercato globale.
Therma Bright (TSXV: THRM) (OTCQB: TBRIF) informa sobre resultados iniciales positivos de ensayos clínicos para el dispositivo PREVA™ para accidente cerebrovascular isquémico, desarrollado por su socio inversor Inretio. Los resultados fueron presentados en la BRAIN Conference 2024 en Londres por el Dr. Gal Yaniv, Director de Neurocirugía Endovascular del Sheba Medical Center. La primera fase de los ensayos clínicos mostró resultados excepcionales, demostrando el potencial del dispositivo para mejorar la atención del accidente cerebrovascular y la recuperación de los pacientes. El CEO de Inretio, Raviv Vine, enfatizó la misión de la empresa de salvar vidas a través de la innovación médica. La exitosa presentación marca un hito significativo mientras Inretio avanza en su programa clínico hacia la entrada en el mercado global.
Therma Bright (TSXV: THRM) (OTCQB: TBRIF)는 투자 파트너 Inretio가 개발한 PREVA™ 허혈성 뇌졸중 장치의 긍정적인 초기 임상 시험 결과를 보고했습니다. 이 결과는 Sheba Medical Center의 혈관내 신경외과장인 Gal Yaniv 박사에 의해 런던에서 열린 BRAIN Conference 2024에서 발표되었습니다. 임상 시험의 1단계는 뛰어난 결과를 보여주었으며, 이 장치가 뇌졸중 치료 및 환자 회복을 개선할 수 있는 잠재력을 나타냅니다. Inretio의 CEO인 Raviv Vine은 의료 혁신을 통해 생명을 구하는 회사의 사명을 강조했습니다. 성공적인 발표는 Inretio가 글로벌 시장 진입을 향해 임상 프로그램을 진행함에 있어 중요한 이정표가 됩니다.
Therma Bright (TSXV: THRM) (OTCQB: TBRIF) annonce des résultats initiaux positifs d'essais cliniques pour le dispositif PREVA™ destiné aux AVC ischémiques, développé par son partenaire d'investissement Inretio. Les résultats ont été présentés lors de la BRAIN Conference 2024 à Londres par le Dr Gal Yaniv, directeur de la neurochirurgie endovasculaire du Sheba Medical Center. La première phase des essais cliniques a montré des résultats exceptionnels, démontrant le potentiel de l'appareil pour améliorer les soins des AVC et la récupération des patients. Le PDG d'Inretio, Raviv Vine, a souligné la mission de l'entreprise de sauver des vies grâce à l'innovation médicale. La présentation réussie marque une étape significative alors qu'Inretio progresse dans son programme clinique vers une entrée sur le marché mondial.
Therma Bright (TSXV: THRM) (OTCQB: TBRIF) berichtet über positive frühe Ergebnisse klinischer Studien für das von seinem Investmentpartner Inretio entwickelte PREVA™-Gerät für ischämischen Schlaganfall. Die Ergebnisse wurden auf der BRAIN Conference 2024 in London von Dr. Gal Yaniv, Direktor der interventionellen Neurochirurgie des Sheba Medical Center, vorgestellt. Die erste Phase der klinischen Studien zeigte außergewöhnliche Ergebnisse und demonstrierte das Potenzial des Geräts zur Verbesserung der Schlaganfallversorgung und der Genesung der Patienten. Der CEO von Inretio, Raviv Vine, betonte die Mission des Unternehmens, Leben durch medizinische Innovation zu retten. Die erfolgreiche Präsentation markiert einen bedeutenden Meilenstein, während Inretio in seinem klinischen Programm auf den globalen Markteintritt hinarbeitet.
- Initial clinical trial results for PREVA™ device demonstrated exceptional outcomes
- Successful presentation of results at prestigious BRAIN Conference 2024
- Progress toward potential commercialization of the stroke treatment device
- None.
Inretio presents initial clinical trial results at prestigious BRAIN Conference 2024 in London.
Toronto, Ontario--(Newsfile Corp. - December 11, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, congratulates its investment partner Inretio on the success of the first phase of the PREVA™ ischemic stroke device.
Per Inretio's LinkedIn post and formal press announcement, https://www.linkedin.com/posts/inretiomd_stroke-strokecare-medicalinnovation-activity-7272282195824705536-VsdS?utm_source=share&utm_medium=member_android key collaborator Dr. Gal Yaniv, Director of Endovascular Neurosurgery from Sheba Medical Center, presented compelling findings from the first phase of the PREVA® device clinical study. The ischemic stroke device results demonstrated exceptional clinical outcomes, validating the potential to reshape stroke care and improve patient recovery.
During the clinical trials, patients treated with the PREVA™ device showed excellent outcomes, which underscore Inretio's commitment to enhancing stroke treatment. Per the announcement, "Each data point reflects more than just success in the lab-it represents a life changed, a family impacted, and a future restored." Raviv Vine, CEO of Inretio, expressed "Our mission is driven by the belief that behind every medical innovation is the opportunity to save lives and offer hope." The presentation at BRAIN Conference marks a critical step forward for Inretio as it continues to advance its clinical program and move closer to bringing this life-changing technology to the global market.
"We're excited that Dr. Yaniv has achieved success during the initial clinical trial of Inretio's PREVA™ Ischemic Stroke device," shared Rob Fia, CEO of Therma Bright. " We look forward to receiving more updates from our partner on their progress, and look to inform our shareholders as these successes are delivered."
Inretio and Therma Bright will provide further updates to the market, as progress is made through the clinical trials.
About Inretio:
Inretio is an Israeli-based medical device company dedicated to revolutionizing ischemic stroke treatment through innovative clot-retriever technology. Its flagship product, the PREVA™ device, ensnares and removes clots, minimizing complications like clot fragmentation and downstream embolism. Inretio's mission is to enhance stroke treatment outcomes for patients, physicians, and healthcare systems worldwide. Visit: www.inretio.co.il.
About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.
Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com
Follow us on Twitter
FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233327
FAQ
What were the results of PREVA™ device's first clinical phase for TBRIF?
Where were the PREVA™ device clinical trial results presented for TBRIF?
What is the current development stage of TBRIF's PREVA™ stroke device?
How did the market respond to TBRIF's PREVA™ device clinical trial results?
